Sequence: GWTLNSAGYLLGKINLKALAALAKKIL
antisense oligonucleotide analogue (anti-TAR)
| Experiment Id | EXP001584 |
|---|---|
| Paper | Synthesis, cellular uptake and HIV-1 Tat-dependent trans-activation inhibition activity of oligonucl |
| Peptide | Transportan |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | no |
| Endosomal Escape Evidence | no |
| Peptide Concentration | 2.5 µM conjugate (5 h) |
| Rna Concentration | 2.5 µM conjugate (5 h) |
| Mixing Ratio | Covalent 1:1 peptide:oligo (disulphide) |
| Formulation Format | Disulphide-linked peptide–oligonucleotide conjugate (peptide has terminal Cys; oligo has 5' C6-thiol; 3' fluorescein label). |
| Formulation Components | Transportan–oligo B (conjugate 13) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | Human foreskin fibroblasts (uptake localization) |
| Animal Model | |
| Administration Route | |
| Output Type | Uptake/localization (confocal microscopy) |
| Output Value | Improved uptake vs HeLa; punctate cytosolic distribution with some membrane association; no nuclear uptake |
| Output Units | |
| Output Notes | Across CPP–oligo conjugates, fluorescence remained confined to cytosolic vesicles with no nuclear localization (consistent with endosomal entrapment). |
| Toxicity Notes | |
| Curation Notes |